RU-58642

RU-58642 is a synthetic compound that belongs to the class of chemical substances known as nonsteroidal antiandrogens (NSAAs). It was developed by the French pharmaceutical company Roussel Uclaf, which is why it is prefixed with "RU".

History

RU-58642 was first synthesized in the late 1980s as part of a series of compounds designed to block the effects of androgens, the male sex hormones. The aim was to develop a drug that could be used in the treatment of conditions such as prostate cancer, which is often driven by androgens.

Mechanism of Action

RU-58642 works by binding to the androgen receptor (AR), a protein found in cells that respond to androgens. By occupying the AR, RU-58642 prevents androgens from binding to it and exerting their effects. This can help to slow the growth of androgen-dependent tumors, such as those found in prostate cancer.

Clinical Trials

Despite showing promise in preclinical studies, RU-58642 has not been extensively tested in humans. The reasons for this are not entirely clear, but may relate to the compound's pharmacokinetic properties or potential side effects.

Potential Applications

In addition to its potential use in prostate cancer, RU-58642 may also have applications in other androgen-dependent conditions, such as benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern baldness). However, further research is needed to confirm these potential uses.

See Also

• Nonsteroidal antiandrogen
• Androgen receptor
• Prostate cancer
• Benign prostatic hyperplasia
• Androgenetic alopecia

This article is a stub related to pharmacology. You can help WikiMD by expanding it!